|
US8212004B2
(en)
|
1999-03-02 |
2012-07-03 |
Human Genome Sciences, Inc. |
Neutrokine-alpha fusion proteins
|
|
US6812327B1
(en)
*
|
1996-10-25 |
2004-11-02 |
Human Genome Sciences, Inc. |
Neutrokine-alpha polypeptides
|
|
WO2001060397A1
(en)
*
|
2000-02-16 |
2001-08-23 |
Genentech, Inc. |
Uses of agonists and antagonists to modulate activity of tnf-related molecules
|
|
GB9828628D0
(en)
|
1998-12-23 |
1999-02-17 |
Glaxo Group Ltd |
Novel ligand
|
|
US7833529B1
(en)
|
1999-01-07 |
2010-11-16 |
Zymogenetics, Inc. |
Methods for inhibiting B lymphocyte proliferation with soluble ztnf4 receptor
|
|
US20050100548A1
(en)
*
|
2001-07-24 |
2005-05-12 |
Biogen Idec Ma Inc. |
BAFF, inhibitors thereof and their use in the modulation of B-cell response
|
|
US20030095967A1
(en)
*
|
1999-01-25 |
2003-05-22 |
Mackay Fabienne |
BAFF, inhibitors thereof and their use in the modulation of B-cell response and treatment of autoimmune disorders
|
|
WO2000068378A1
(en)
|
1999-05-06 |
2000-11-16 |
National Jewish Medical And Research Center |
Tall-1 nucleic acid molecules, proteins, receptors and methods of use thereof
|
|
HK1043608B
(en)
|
1999-08-17 |
2007-12-07 |
Biogen Ma Inc. |
Baff receptor (bcma), an immunoregulatory agent
|
|
UA74798C2
(uk)
*
|
1999-10-06 |
2006-02-15 |
Байоджен Айдек Ма Інк. |
Спосіб лікування раку у ссавця за допомогою поліпептиду, що протидіє взаємодії april з його рецепторами
|
|
US20040002068A1
(en)
|
2000-03-01 |
2004-01-01 |
Corixa Corporation |
Compositions and methods for the detection, diagnosis and therapy of hematological malignancies
|
|
US7371388B1
(en)
|
2000-05-04 |
2008-05-13 |
Human Genome Sciences, Inc. |
Treatment of Sjogren's syndrome by administration of TR18 polypeptides
|
|
AU2001263114A1
(en)
*
|
2000-05-12 |
2001-11-26 |
Amgen Inc |
Methods and compositions of matter concerning april/g70, bcma, blys/agp-3, and taci
|
|
AU2001268427B2
(en)
|
2000-06-16 |
2007-03-29 |
Glaxosmithkline Intellectual Property Limited |
Antibodies that immunospecifically bind to blys
|
|
US7879328B2
(en)
*
|
2000-06-16 |
2011-02-01 |
Human Genome Sciences, Inc. |
Antibodies that immunospecifically bind to B lymphocyte stimulator
|
|
AU2001288301A1
(en)
|
2000-08-18 |
2002-03-04 |
Human Genome Sciences, Inc. |
Binding polypeptides and methods based thereon
|
|
UA83458C2
(uk)
*
|
2000-09-18 |
2008-07-25 |
Байоджен Айдек Ма Інк. |
Виділений поліпептид baff-r (рецептор фактора активації в-клітин сімейства tnf)
|
|
DE10049010A1
(de)
*
|
2000-10-04 |
2002-04-18 |
Boehringer Ingelheim Int |
Transferrin-Polykation/DNS-Komplexe für die systemische Therapie von Tumorerkrankungen mit zytotoxischen Proteinen
|
|
PL403488A1
(pl)
|
2001-05-24 |
2013-07-08 |
Zymogenetics, Inc. |
Zastosowanie bialka fuzyjnego TACI-immunoglobulina, bialko fuzyjne, czasteczka kwasu nukleinowego kodujaca bialko fuzyjne, kompozycja farmaceutyczna i sposób wytwarzania bialka fuzyjnego TACI-immunoglobulina
|
|
KR20040019105A
(ko)
*
|
2001-08-03 |
2004-03-04 |
제넨테크, 인크. |
TACIs 및 BR3 폴리펩티드 및 이의 용도
|
|
AU2003221256A1
(en)
*
|
2002-02-21 |
2003-09-09 |
Biogen Idec Ma Inc. |
Use of bcma as an immunoregulatory agent
|
|
BR0313033A
(pt)
*
|
2002-07-25 |
2007-07-10 |
Genentech Inc |
anticorpos, anticorpos monoclonais, linhagens de células de hibridoma, anticorpos receptores de anti-taci isolados, anticorpos anti -taci, métodos de modulação da atividade biológica
|
|
EP1608730B1
(en)
*
|
2003-03-28 |
2013-11-06 |
Biogen Idec MA Inc. |
Truncated baff receptors
|
|
ES2537738T3
(es)
*
|
2003-06-05 |
2015-06-11 |
Genentech, Inc. |
Terapia de combinación para trastornos de células B
|
|
US20050163775A1
(en)
*
|
2003-06-05 |
2005-07-28 |
Genentech, Inc. |
Combination therapy for B cell disorders
|
|
WO2005042009A1
(en)
|
2003-10-20 |
2005-05-12 |
Biogen Idec Ma Inc. |
Therapeutic regimens for baff antagonists
|
|
WO2005075511A1
(en)
*
|
2004-01-29 |
2005-08-18 |
Genentech, Inc. |
Variants of the extracellular domain of bcma and uses thereof
|
|
EP1812472A1
(en)
*
|
2004-11-04 |
2007-08-01 |
Genentech, Inc. |
Polypeptides that bind baff and/or april
|
|
AU2005318086B2
(en)
*
|
2004-12-23 |
2011-07-07 |
Merck Serono Sa |
BCMA polypeptides and uses thereof
|
|
US20080254030A1
(en)
*
|
2005-01-28 |
2008-10-16 |
Charles Mackay |
Use of Baff to Treat Th2-Mediated Conditions
|
|
US8808696B2
(en)
|
2005-08-09 |
2014-08-19 |
Ares Trading S.A. |
Methods for the treatment and prevention of abnormal cell proliferation using TACI-fusion molecules
|
|
KR20080056714A
(ko)
|
2005-08-09 |
2008-06-23 |
지모제넥틱스, 인코포레이티드 |
TACI―Ig 융합 분자를 사용하여 B―세포 악성종양을치료하는 방법
|
|
KR20080074120A
(ko)
*
|
2005-10-13 |
2008-08-12 |
휴먼 게놈 사이언시즈, 인코포레이티드 |
자가항체 양성 질환 환자의 치료에 유용한 방법 및 조성물
|
|
US9168286B2
(en)
|
2005-10-13 |
2015-10-27 |
Human Genome Sciences, Inc. |
Methods and compositions for use in treatment of patients with autoantibody positive disease
|
|
MY149159A
(en)
|
2005-11-15 |
2013-07-31 |
Hoffmann La Roche |
Method for treating joint damage
|
|
CA2629306A1
(en)
|
2005-11-23 |
2007-05-31 |
Genentech, Inc. |
Methods and compositions related to b cell assays
|
|
WO2007123765A2
(en)
|
2006-03-31 |
2007-11-01 |
Human Genome Sciences Inc. |
Neutrokine-alpha and neutrokine-alpha splice variant
|
|
WO2007134326A2
(en)
|
2006-05-15 |
2007-11-22 |
Ares Trading S.A. |
Methods for treating autoimmune diseases using a taci-ig fusion molecule
|
|
AU2009272771B2
(en)
*
|
2008-07-17 |
2012-09-20 |
Novartis Ag |
Compositions and methods of use for therapeutic antibodies
|
|
WO2010075249A2
(en)
|
2008-12-22 |
2010-07-01 |
Genentech, Inc. |
A method for treating rheumatoid arthritis with b-cell antagonists
|
|
EP2396035A4
(en)
*
|
2009-02-12 |
2012-09-12 |
Human Genome Sciences Inc |
USE OF ANTAGONISTS OF THE B-LYMPHOCYTE STIMULATOR PROTEIN TO PROMOTE TRANSPLANT TOLERANCE
|
|
CN102421801B
(zh)
|
2009-03-10 |
2016-03-16 |
比奥根Ma公司 |
抗-bcma抗体
|
|
JP5996429B2
(ja)
|
2009-09-03 |
2016-09-21 |
ジェネンテック, インコーポレイテッド |
関節リウマチの治療、診断及びモニターするための方法
|
|
CN101781680B
(zh)
*
|
2009-10-19 |
2012-05-09 |
南通大学附属医院 |
测定对人baff-r基因启动子活性影响因素的方法
|
|
WO2011108008A2
(en)
*
|
2010-03-04 |
2011-09-09 |
Transgene Biotek Ltd. |
Antibody for targeted induction of apoptosis, cdc and adcc mediated killing of cancer cells, tbl-cln1
|
|
RU2013140975A
(ru)
|
2011-02-28 |
2015-04-10 |
Дженентек, Инк. |
Биологические маркеры и способы прогнозирования восприимчивости к антагонистам в-клеток
|
|
EP2714737A1
(en)
*
|
2011-05-27 |
2014-04-09 |
Glaxo Group Limited |
Bcma (cd269/tnfrsf17) -binding proteins
|
|
UA112434C2
(uk)
|
2011-05-27 |
2016-09-12 |
Ґлаксо Ґруп Лімітед |
Антигензв'язувальний білок, який специфічно зв'язується з всма
|
|
TWI679212B
(zh)
|
2011-11-15 |
2019-12-11 |
美商安進股份有限公司 |
針對bcma之e3以及cd3的結合分子
|
|
WO2013116287A1
(en)
|
2012-01-31 |
2013-08-08 |
Genentech, Inc. |
Anti-ig-e m1' antibodies and methods using same
|
|
US10435474B2
(en)
|
2013-12-24 |
2019-10-08 |
Ossianix, Inc. |
Baff selective binding compounds and related methods
|
|
ES2959480T3
(es)
|
2014-02-07 |
2024-02-26 |
Univ Mcmaster |
Acoplador de células T - antígeno trifuncional y métodos y usos del mismo
|
|
CN122399016A
(zh)
|
2014-03-15 |
2026-07-17 |
诺华股份有限公司 |
使用嵌合抗原受体治疗癌症
|
|
JP2017528433A
(ja)
|
2014-07-21 |
2017-09-28 |
ノバルティス アーゲー |
低い免疫増強用量のmTOR阻害剤とCARの組み合わせ
|
|
AU2015292744C1
(en)
|
2014-07-21 |
2021-01-21 |
Novartis Ag |
Treatment of cancer using humanized anti-BCMA chimeric antigen receptor
|
|
US10577417B2
(en)
|
2014-09-17 |
2020-03-03 |
Novartis Ag |
Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy
|
|
CN113698497A
(zh)
|
2014-12-05 |
2021-11-26 |
纪念斯隆-凯特琳癌症中心 |
靶向b-细胞成熟抗原的嵌合抗原受体及其用途
|
|
HRP20210582T1
(hr)
|
2014-12-05 |
2021-09-03 |
Memorial Sloan Kettering Cancer Center |
Antitijela koja ciljaju antigen sazrijevanja b-stanice i postupci uporabe
|
|
AU2015357535B2
(en)
|
2014-12-05 |
2020-05-14 |
Eureka Therapeutics, Inc. |
Antibodies targeting G-protein coupled receptor and methods of use
|
|
WO2016126608A1
(en)
|
2015-02-02 |
2016-08-11 |
Novartis Ag |
Car-expressing cells against multiple tumor antigens and uses thereof
|
|
TWI700298B
(zh)
|
2015-04-13 |
2020-08-01 |
美商輝瑞股份有限公司 |
靶向b細胞成熟抗原之嵌合型抗原受體類
|
|
HUE057285T2
(hu)
|
2015-04-13 |
2022-04-28 |
Pfizer |
Terápiás ellenanyagok és alkalmazásaik
|
|
WO2016172583A1
(en)
|
2015-04-23 |
2016-10-27 |
Novartis Ag |
Treatment of cancer using chimeric antigen receptor and protein kinase a blocker
|
|
US11667691B2
(en)
|
2015-08-07 |
2023-06-06 |
Novartis Ag |
Treatment of cancer using chimeric CD3 receptor proteins
|
|
ES2987957T3
(es)
|
2015-11-23 |
2024-11-18 |
Novartis Ag |
Vectores de transferencia lentivirales optimizados y usos de los mismos
|
|
KR20180099768A
(ko)
|
2015-12-30 |
2018-09-05 |
노파르티스 아게 |
증진된 효능을 갖는 면역 이펙터 세포 요법
|
|
MA44254A
(fr)
|
2016-02-17 |
2018-12-26 |
Seattle Genetics Inc |
Anticorps bcma et leur utilisation pour traiter le cancer et les troubles immunologiques
|
|
EP3432924A1
(en)
|
2016-03-23 |
2019-01-30 |
Novartis AG |
Cell secreted minibodies and uses thereof
|
|
US11136405B2
(en)
*
|
2016-06-06 |
2021-10-05 |
Board Of Regents, The Unviersity Of Texas System |
BAFF-R antibodies and uses thereof
|
|
IL299221A
(en)
|
2016-06-21 |
2023-02-01 |
Teneobio Inc |
Cd3 binding antibodies
|
|
CR20220578A
(es)
|
2016-09-14 |
2023-01-17 |
Teneobio Inc |
Anticuerpos de unión a cd3
|
|
WO2018111340A1
(en)
|
2016-12-16 |
2018-06-21 |
Novartis Ag |
Methods for determining potency and proliferative function of chimeric antigen receptor (car)-t cells
|
|
EP3559035A1
(en)
|
2016-12-21 |
2019-10-30 |
TeneoBio, Inc. |
Anti-bcma heavy chain-only antibodies
|
|
US11535662B2
(en)
|
2017-01-26 |
2022-12-27 |
Novartis Ag |
CD28 compositions and methods for chimeric antigen receptor therapy
|
|
US20190375815A1
(en)
|
2017-01-31 |
2019-12-12 |
Novartis Ag |
Treatment of cancer using chimeric t cell receptor proteins having multiple specificities
|
|
WO2018160731A1
(en)
|
2017-02-28 |
2018-09-07 |
Novartis Ag |
Shp inhibitor compositions and uses for chimeric antigen receptor therapy
|
|
EP3615055A1
(en)
|
2017-04-28 |
2020-03-04 |
Novartis AG |
Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor
|
|
EP3615068A1
(en)
|
2017-04-28 |
2020-03-04 |
Novartis AG |
Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor
|
|
BR112019023608A2
(pt)
|
2017-05-12 |
2020-05-26 |
Crispr Therapeutics Ag |
Materiais e métodos para células manipuladas e seus usos em imuno-oncologia
|
|
US11166985B2
(en)
|
2017-05-12 |
2021-11-09 |
Crispr Therapeutics Ag |
Materials and methods for engineering cells and uses thereof in immuno-oncology
|
|
WO2018229715A1
(en)
|
2017-06-16 |
2018-12-20 |
Novartis Ag |
Compositions comprising anti-cd32b antibodies and methods of use thereof
|
|
CN110891971B
(zh)
|
2017-06-20 |
2024-01-12 |
特尼奥生物股份有限公司 |
仅有重链的抗bcma抗体
|
|
SG10201913147WA
(en)
|
2017-07-11 |
2020-02-27 |
Compass Therapeutics Llc |
Agonist antibodies that bind human cd137 and uses thereof
|
|
WO2019035938A1
(en)
|
2017-08-16 |
2019-02-21 |
Elstar Therapeutics, Inc. |
MULTISPECIFIC MOLECULES BINDING TO BCMA AND USES THEREOF
|
|
EP3694997A4
(en)
|
2017-10-12 |
2021-06-30 |
Mcmaster University |
T cell-antigen coupler with y182t mutation and methods and uses thereof
|
|
SG11202003415XA
(en)
|
2017-10-18 |
2020-05-28 |
Novartis Ag |
Compositions and methods for selective protein degradation
|
|
WO2019081983A1
(en)
|
2017-10-25 |
2019-05-02 |
Novartis Ag |
CD32B TARGETING ANTIBODIES AND METHODS OF USE
|
|
US11718679B2
(en)
|
2017-10-31 |
2023-08-08 |
Compass Therapeutics Llc |
CD137 antibodies and PD-1 antagonists and uses thereof
|
|
US20210179709A1
(en)
|
2017-10-31 |
2021-06-17 |
Novartis Ag |
Anti-car compositions and methods
|
|
US11066475B2
(en)
|
2017-11-01 |
2021-07-20 |
Juno Therapeutics, Inc. |
Chimeric antigen receptors specific for B-cell maturation antigen and encoding polynucleotides
|
|
MA49911A
(fr)
|
2017-11-01 |
2020-06-24 |
Juno Therapeutics Inc |
Anticorps et récepteurs antigéniques chimériques spécifiques de l'antigene de maturation des lymphocytes b
|
|
AU2018359907A1
(en)
|
2017-11-06 |
2020-05-07 |
Fred Hutchinson Cancer Center |
Combination of a cell therapy and a gamma secretase inhibitor
|
|
WO2019099639A1
(en)
|
2017-11-15 |
2019-05-23 |
Navartis Ag |
Bcma-targeting chimeric antigen receptor, cd19-targeting chimeric antigen receptor, and combination therapies
|
|
EP3713961A2
(en)
|
2017-11-20 |
2020-09-30 |
Compass Therapeutics LLC |
Cd137 antibodies and tumor antigen-targeting antibodies and uses thereof
|
|
MX2020005651A
(es)
|
2017-11-30 |
2020-10-28 |
Novartis Ag |
Receptor de antigeno quimerico dirigido a bcma y usos del mismo.
|
|
WO2019136432A1
(en)
|
2018-01-08 |
2019-07-11 |
Novartis Ag |
Immune-enhancing rnas for combination with chimeric antigen receptor therapy
|
|
US12247060B2
(en)
|
2018-01-09 |
2025-03-11 |
Marengo Therapeutics, Inc. |
Calreticulin binding constructs and engineered T cells for the treatment of diseases
|
|
AU2019215031C1
(en)
|
2018-01-31 |
2026-02-26 |
Novartis Ag |
Combination therapy using a chimeric antigen receptor
|
|
WO2019160956A1
(en)
|
2018-02-13 |
2019-08-22 |
Novartis Ag |
Chimeric antigen receptor therapy in combination with il-15r and il15
|
|
EP3765517A1
(en)
|
2018-03-14 |
2021-01-20 |
Elstar Therapeutics, Inc. |
Multifunctional molecules that bind to calreticulin and uses thereof
|
|
US20210047405A1
(en)
|
2018-04-27 |
2021-02-18 |
Novartis Ag |
Car t cell therapies with enhanced efficacy
|
|
US20210396739A1
(en)
|
2018-05-01 |
2021-12-23 |
Novartis Ag |
Biomarkers for evaluating car-t cells to predict clinical outcome
|
|
US20200063100A1
(en)
|
2018-05-11 |
2020-02-27 |
Crispr Therapeutics Ag |
Methods and compositions for treating cancer
|
|
US20210213063A1
(en)
|
2018-05-25 |
2021-07-15 |
Novartis Ag |
Combination therapy with chimeric antigen receptor (car) therapies
|
|
PE20210320A1
(es)
|
2018-06-01 |
2021-02-16 |
Novartis Ag |
Moleculas de union contra bcma y usos de las mismas
|
|
WO2019237035A1
(en)
|
2018-06-08 |
2019-12-12 |
Intellia Therapeutics, Inc. |
Compositions and methods for immunooncology
|
|
IL279367B2
(en)
|
2018-06-13 |
2026-05-01 |
Novartis Ag |
BCMA chimeric antigen receptors and their uses
|
|
WO2020010250A2
(en)
|
2018-07-03 |
2020-01-09 |
Elstar Therapeutics, Inc. |
Anti-tcr antibody molecules and uses thereof
|
|
AR116109A1
(es)
|
2018-07-10 |
2021-03-31 |
Novartis Ag |
Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
|
|
US11110123B2
(en)
|
2018-07-17 |
2021-09-07 |
Triumvira Immunologics Usa, Inc. |
T cell-antigen coupler with various construct optimizations
|
|
LT4324851T
(lt)
|
2018-07-19 |
2025-10-10 |
|
Chimeriniai antigeno receptoriai, pasižymintys bcma specifiškumu, ir jų panaudojimas
|
|
TWI838389B
(zh)
|
2018-07-19 |
2024-04-11 |
美商再生元醫藥公司 |
雙特異性抗-BCMAx抗-CD3抗體及其用途
|
|
SI3844267T1
(sl)
|
2018-08-31 |
2025-10-30 |
Novartis Ag |
Postopki izdelave celic, ki izražajo receptorje himernega antigena
|
|
US20210171909A1
(en)
|
2018-08-31 |
2021-06-10 |
Novartis Ag |
Methods of making chimeric antigen receptor?expressing cells
|
|
US12473345B2
(en)
|
2018-11-01 |
2025-11-18 |
Juno Therapeutics, Inc. |
Methods for treatment using chimeric antigen receptors specific for B-cell maturation antigen
|
|
KR20210099614A
(ko)
|
2018-12-04 |
2021-08-12 |
노파르티스 아게 |
Cd3에 대한 결합 분자 및 이의 용도
|
|
AU2019402189B2
(en)
|
2018-12-20 |
2023-04-13 |
Novartis Ag |
Dosing regimen and pharmaceutical combination comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives
|
|
EP3924054B1
(en)
|
2019-02-15 |
2025-04-02 |
Novartis AG |
3-(1-oxo-5-(piperidin-4-yl)isoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
|
|
CA3123519A1
(en)
|
2019-02-15 |
2020-08-20 |
Novartis Ag |
Substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
|
|
AU2020226893B2
(en)
|
2019-02-21 |
2025-02-27 |
Marengo Therapeutics, Inc. |
Multifunctional molecules that bind to T cell related cancer cells and uses thereof
|
|
JP7579795B2
(ja)
|
2019-02-21 |
2024-11-08 |
マレンゴ・セラピューティクス,インコーポレーテッド |
NKp30に結合する抗体分子およびその使用
|
|
US20220152150A1
(en)
|
2019-02-25 |
2022-05-19 |
Novartis Ag |
Mesoporous silica particles compositions for viral delivery
|
|
EP3942025A1
(en)
|
2019-03-21 |
2022-01-26 |
Novartis AG |
Car-t cell therapies with enhanced efficacy
|
|
CA3133654A1
(en)
|
2019-04-05 |
2020-10-08 |
Teneobio, Inc. |
Heavy chain antibodies binding to psma
|
|
WO2020210678A1
(en)
|
2019-04-12 |
2020-10-15 |
Novartis Ag |
Methods of making chimeric antigen receptor-expressing cells
|
|
WO2020219742A1
(en)
|
2019-04-24 |
2020-10-29 |
Novartis Ag |
Compositions and methods for selective protein degradation
|
|
CA3138633A1
(en)
|
2019-04-30 |
2020-11-05 |
Crispr Therapeutics Ag |
Allogeneic cell therapy of b cell malignancies using genetically engineered t cells targeting cd19
|
|
UY38701A
(es)
|
2019-05-21 |
2020-12-31 |
Novartis Ag |
Moléculas de unión a cd19, conjugados, composiciones que las comprenden y usos de las mismas
|
|
AU2020279224B2
(en)
|
2019-05-21 |
2024-12-05 |
Novartis Ag |
Trispecific binding molecules against BCMA and uses thereof
|
|
CN114206927B
(zh)
|
2019-06-14 |
2025-03-21 |
特尼奥生物股份有限公司 |
与cd22和cd3结合的多特异性重链抗体
|
|
BR112021026832A2
(pt)
|
2019-07-02 |
2022-05-10 |
Hutchinson Fred Cancer Res |
Vetores ad35 recombinantes e aprimoramentos da terapia gênica relacionada
|
|
AU2020382219A1
(en)
|
2019-11-13 |
2022-05-12 |
Crispr Therapeutics Ag |
Manufacturing process for making T cells expressing chimeric antigen receptors
|
|
WO2021108661A2
(en)
|
2019-11-26 |
2021-06-03 |
Novartis Ag |
Chimeric antigen receptors and uses thereof
|
|
WO2021113776A1
(en)
|
2019-12-06 |
2021-06-10 |
Juno Therapeutics, Inc. |
Anti-idiotypic antibodies to bcma-targeted binding domains and related compositions and methods
|
|
US20230057071A1
(en)
|
2019-12-20 |
2023-02-23 |
Novartis Ag |
Combination of anti tim-3 antibody mbg453 and anti tgf-beta antibody nis793, with or without decitabine or the anti pd-1 antibody spartalizumab, for treating myelofibrosis and myelodysplastic syndrome
|
|
WO2021138474A2
(en)
|
2020-01-03 |
2021-07-08 |
Marengo Therapeutics, Inc. |
Anti-tcr antibody molecules and uses thereof
|
|
IL295878A
(en)
|
2020-02-27 |
2022-10-01 |
Novartis Ag |
Methods for producing cells expressing a chimeric antigen receptor
|
|
JP2023516008A
(ja)
|
2020-02-27 |
2023-04-17 |
ノバルティス アーゲー |
キメラ抗原受容体発現細胞を作製する方法
|
|
KR20250007022A
(ko)
|
2020-04-29 |
2025-01-13 |
테네오원, 인코포레이티드 |
변형된 중쇄 불변 영역을 갖는 다중특이적 중쇄 항체
|
|
US20230332104A1
(en)
|
2020-06-11 |
2023-10-19 |
Novartis Ag |
Zbtb32 inhibitors and uses thereof
|
|
EP4168007A1
(en)
|
2020-06-23 |
2023-04-26 |
Novartis AG |
Dosing regimen comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives
|
|
US12551669B2
(en)
|
2020-07-15 |
2026-02-17 |
Biogen Ma Inc. |
Medical system including two access ports
|
|
IL299904B1
(en)
|
2020-07-20 |
2026-05-01 |
Cerebral Therapeutics Inc |
Liquid catheter device for recording brain status
|
|
EP4188549A1
(en)
|
2020-08-03 |
2023-06-07 |
Novartis AG |
Heteroaryl substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
|
|
AU2021324761A1
(en)
*
|
2020-08-12 |
2023-03-16 |
The Board Of Trustees Of The Leland Stanford Junior University |
sBCMA variants and Fc fusion proteins thereof
|
|
WO2022040586A2
(en)
|
2020-08-21 |
2022-02-24 |
Novartis Ag |
Compositions and methods for in vivo generation of car expressing cells
|
|
TW202304979A
(zh)
|
2021-04-07 |
2023-02-01 |
瑞士商諾華公司 |
抗TGFβ抗體及其他治療劑用於治療增殖性疾病之用途
|
|
CA3214757A1
(en)
|
2021-04-08 |
2022-10-13 |
Andreas Loew |
Multifuntional molecules binding to tcr and uses thereof
|
|
AR125468A1
(es)
|
2021-04-27 |
2023-07-19 |
Novartis Ag |
Sistema de producción de vectores virales
|
|
AU2022283819A1
(en)
|
2021-06-01 |
2024-01-04 |
Triumvira Immunologics Usa, Inc. |
Claudin 18.2 t cell-antigen couplers and uses thereof
|
|
US11453723B1
(en)
|
2021-06-25 |
2022-09-27 |
Mcmaster University |
BCMA T cell-antigen couplers and uses thereof
|
|
CA3228678A1
(en)
|
2021-08-11 |
2023-02-16 |
Amato J. Giaccia |
Methods of reducing production of iga, igm and/or igg using sbcma variants and fc fusion proteins thereof
|
|
EP4388000A1
(en)
|
2021-08-20 |
2024-06-26 |
Novartis AG |
Methods of making chimeric antigen receptor?expressing cells
|
|
US12605537B2
(en)
|
2022-02-15 |
2026-04-21 |
Biogen Ma Inc. |
Implantable medical device for use with or having recording electrode
|
|
WO2023214325A1
(en)
|
2022-05-05 |
2023-11-09 |
Novartis Ag |
Pyrazolopyrimidine derivatives and uses thereof as tet2 inhibitors
|
|
JP2026519263A
(ja)
|
2022-10-26 |
2026-06-15 |
ノバルティス アーゲー |
レンチウイルス製剤
|
|
TW202440636A
(zh)
|
2023-03-21 |
2024-10-16 |
美商傳記55有限公司 |
Cd19/cd38多特異性抗體
|
|
WO2024243441A1
(en)
|
2023-05-24 |
2024-11-28 |
Kumquat Biosciences Inc. |
Heterocyclic compounds and uses thereof
|
|
WO2025170844A1
(en)
*
|
2024-02-05 |
2025-08-14 |
Board Of Regents, The University Of Texas System |
Chimeric polypeptides and methods of use
|
|
WO2026050572A2
(en)
|
2024-08-29 |
2026-03-05 |
Marengo Therapeutics, Inc. |
Multifunctional molecules binding to tcr and uses thereof
|